학술논문
Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting
Document Type
Article
Author
Source
In: Hematological Oncology . (Hematological Oncology, December 2020, 38(5):726-736)
Subject
Language
English
ISSN
10991069
02780232
02780232